justbacked

Biopharma, Biotechnology, Genetics

Cloverleaf Bio

Cloverleaf Bio raised $33M in a Seed announced on Sep 8, 2026, led by Eli Lilly, Draper Associates, AbbVie, Mission BioCapital, Boehringer Ingelheim Venture Fund. Since then it has posted 3 roles (3 still open), the first 27 days after it. Another 1 open role was posted before the announcement. With 4 open roles it is hiring more than 28% of the 147 Seed startups on JustBacked (median: 6). In total it has raised $33M over 2 rounds from 7 investors.

Roles posted per month since the round
  • October 20262
  • November 20261

From Cloverleaf Bio's own hiring system, by posting date. Tracked since Oct 1, 2026; roles that closed before then aren't counted.

Cloverleaf Bio develops an RNA therapeutic platform for oncology.

Why join Cloverleaf Bio?

The bet: a new class of RNA medicines could become a core oncology tool, and Cloverleaf Bio, a New Haven biotech, is building the platform behind it. If it works, oncology gets a new kind of medicine that Eli Lilly, AbbVie and Boehringer Ingelheim already want a piece of. Its $33M seed beats 90% of its stage's rounds, and a team of 1-10 has room for early hires to shape the science.

JustBacked's take, based on Cloverleaf Bio's own site and its funding and hiring data.

Seed · $33M · 74d agocloverleafbio.com

Hiring velocity

Open roles
4
Added, 30 days
+1
Added, 7 days
+1
Closed, 30 days
0
Raised
74 days ago
Led by
Eli Lilly, Draper Associates, AbbVie, Mission BioCapital, Boehringer Ingelheim Venture Fund
Team size
1-10
HQ
New Haven, Connecticut, United States
Newest role
4d ago
Tracked since
Oct 1, 2026

Where they're hiring

Science4

Open roles at Cloverleaf Bio

Source: cloverleaf-bio.breezy.hr, checked daily.